drugset / Trial / NCT06450145

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

NCT06450145

NaSingle-groupOpen-labelTreatment

Summary

This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients were treated with interferon α-2b, arsenic and venetoclax. The efficacy (ORR) and safety were evaluated.

Timeline

Start
2024-05-01
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule
Subject arsenic trioxide Small molecule
Subject interferon alfa-2b Protein / enzyme biologic

Indications